Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Br J Dermatol
; 173(6): 1387-99, 2015 Dec.
Article
in En
| MEDLINE
| ID: mdl-26357944
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Thalidomide
/
Anti-Inflammatory Agents, Non-Steroidal
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Br J Dermatol
Year:
2015
Type:
Article
Affiliation country:
France